ATE338557T1 - Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks - Google Patents

Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks

Info

Publication number
ATE338557T1
ATE338557T1 AT02738138T AT02738138T ATE338557T1 AT E338557 T1 ATE338557 T1 AT E338557T1 AT 02738138 T AT02738138 T AT 02738138T AT 02738138 T AT02738138 T AT 02738138T AT E338557 T1 ATE338557 T1 AT E338557T1
Authority
AT
Austria
Prior art keywords
tic
cox2 inhibitors
treat schizophrenia
schizophrenia
treat
Prior art date
Application number
AT02738138T
Other languages
English (en)
Inventor
Norbert Mueller
Original Assignee
Norbert Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129320A external-priority patent/DE10129320A1/de
Application filed by Norbert Mueller filed Critical Norbert Mueller
Application granted granted Critical
Publication of ATE338557T1 publication Critical patent/ATE338557T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02738138T 2001-06-19 2002-05-31 Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks ATE338557T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129320A DE10129320A1 (de) 2001-06-19 2001-06-19 Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US36490402P 2002-03-14 2002-03-14

Publications (1)

Publication Number Publication Date
ATE338557T1 true ATE338557T1 (de) 2006-09-15

Family

ID=26009543

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05024864T ATE452642T1 (de) 2001-06-19 2002-05-31 Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
AT02738138T ATE338557T1 (de) 2001-06-19 2002-05-31 Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05024864T ATE452642T1 (de) 2001-06-19 2002-05-31 Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen

Country Status (16)

Country Link
US (1) US20040204469A1 (de)
EP (2) EP1397145B1 (de)
JP (2) JP4205577B2 (de)
AP (1) AP1512A (de)
AT (2) ATE452642T1 (de)
AU (1) AU2002312967A1 (de)
CA (1) CA2448025C (de)
CY (1) CY1109949T1 (de)
DE (2) DE60214542T2 (de)
DK (2) DK1627639T3 (de)
EA (1) EA009780B1 (de)
ES (2) ES2271269T3 (de)
OA (1) OA12627A (de)
PT (2) PT1627639E (de)
SI (1) SI1627639T1 (de)
WO (1) WO2002102297A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2006514934A (ja) * 2002-11-26 2006-05-18 アレックザ ファーマシューティカルズ， インコーポレイテッド 疼痛治療用薬剤製造のためのロキサピンまたはアモキサピンの使用
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
EP1633360A1 (de) * 2003-05-16 2006-03-15 Pfizer Products Incorporated Behandlung von psychotischen und depressiven erkrankungen
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
JP2007511569A (ja) * 2003-11-19 2007-05-10 グラクソ　グループ　リミテッド 鬱病性障害の治療用のシクロオキシゲナーゼ−２阻害剤の使用
EP1687001A2 (de) * 2003-11-19 2006-08-09 Glaxo Group Limited Verwendung von cyclooxygenase-2-selektiven hemmern zur behandlung von schizophrenie
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
JP2007526328A (ja) * 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1781360A1 (de) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol-arzneiabgabevorrichtung mit perkussiv aktivierten wärmepackungen
US20070281927A1 (en) * 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
JP5144104B2 (ja) 2007-04-09 2013-02-13 ユニ・チャーム株式会社 伸縮性複合シート及びそれを用いた使い捨て着用物品
JP2013507394A (ja) * 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
EP2340819A1 (de) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Zusammensetzungen mit Venlafaxin und Celecoxib zur Behandlung von Schmerzen
EP2340818A1 (de) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Kokristalle von Venlafaxin und Celecoxib
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579846A (en) * 1984-10-11 1986-04-01 Pfizer Inc. Antiinflammatory compositions and methods
WO1999025353A1 (en) * 1997-11-13 1999-05-27 Merck Sharp & Dohme Limited Therapeutic uses of triazolo-pyridazine derivatives
DE60022692T2 (de) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
EP1142889A1 (de) * 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazolderivate als entzündungs-/schmerzhemmende Mittel
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor

Also Published As

Publication number Publication date
EA009780B1 (ru) 2008-04-28
PT1627639E (pt) 2010-03-01
AU2002312967A1 (en) 2003-01-02
ES2336682T3 (es) 2010-04-15
WO2002102297A3 (en) 2003-05-01
ATE452642T1 (de) 2010-01-15
PT1397145E (pt) 2006-10-31
OA12627A (en) 2006-06-13
CY1109949T1 (el) 2014-09-10
CA2448025A1 (en) 2002-12-27
AP1512A (en) 2005-12-15
EP1397145A2 (de) 2004-03-17
JP4205577B2 (ja) 2009-01-07
JP2004534066A (ja) 2004-11-11
EP1627639A3 (de) 2006-09-27
DE60214542T2 (de) 2006-12-21
WO2002102297A2 (en) 2002-12-27
CA2448025C (en) 2011-07-05
DE60234873D1 (de) 2010-02-04
DK1627639T3 (da) 2010-04-26
JP4824727B2 (ja) 2011-11-30
EP1397145B1 (de) 2006-09-06
DE60214542D1 (de) 2006-10-19
JP2008297308A (ja) 2008-12-11
ES2271269T3 (es) 2007-04-16
EA200301291A1 (ru) 2004-06-24
DK1397145T3 (da) 2007-01-02
SI1627639T1 (sl) 2010-04-30
EP1627639A2 (de) 2006-02-22
AP2003002934A0 (en) 2003-12-31
EP1627639B1 (de) 2009-12-23
US20040204469A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
ATE338557T1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
ATE473753T1 (de) Verwendung von botulinum toxin zur behandlung von post-operative schmerzen
EP1438054A4 (de) Verfahren und zusammensetzungen zur behandlung von flaviviren und pestiviren mit 4'-modifiziertem nucleosid
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE410421T1 (de) P38 inhibitor und anwendungsverfahren dafür
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
ATE307597T1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE353218T1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
DE60221798D1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ATE509621T1 (de) Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
DE60226855D1 (de) Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
ATE290786T1 (de) Fungizide zusammensetzung und verwendung dieser zusammensetzung zur bekämpfung von pflanzenkrankheiten
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE333452T1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderiva e und deren verwendung zur behandlung von schmerzen,angstzuständen oder erkrankungen des magen-darm- trakts

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397145

Country of ref document: EP